Study Enrollment

Your details will not be published or shared.

Clinical Trial

20-041-NCP: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer (BESPOKE CRC)

The purpose of this study is to determine the how many colorectal cancer patients have their treatment regimen changed by their treating physician due to the results of their SIGNATERA ctDNA test. A test called SIGNATERA will screen tissue and blood taken from colorectal cancer patients in order to find mutations. Data and blood samples will be collected for 2 years on each patient enrolled. It is hoped that the test results will assist the treating physician with determining chemotherapy treatment for this patient population.

Eligibility Criteria

  • Inclusion: 18 years or older Planned or undergone colorectal surgery for cancer Diagnosis of colorectal cancer ECOG 2 or less Able to receive post-operative chemotherapy Exclusion: Pregnant or breastfeeding Secondary cancer (exception: non-melanoma skin cancer) Neuropathy > grade 2

Contact Information

    Alexander Ward, PhD

    (706) 721-1623